RSS | Login | Register

James G. Dickinson

Recent Articles

As I See It: The threat to FDA independence

May 01, 2012

There are claims that a politically independent FDA belongs in "a world that doesn't exist any more"

Woodcock: Hill should hold line on standards

May 01, 2012

FDA drugs director Janet Woodcock told the House Energy and Commerce Committee in March that Congress should not change the standards for determining a therapy's safety and effectiveness

FDA work integrity rises, survey says

May 01, 2012

A Union of Concerned Scientists survey of 997 FDA scientists suggests that agency leaders are helping to boost scientific integrity but still are beset by interference from special interests.

Project FDA spurs industry efficiency

April 01, 2012

Former FDA commissioner Andrew von Eschenbach has joined the Manhattan Institute to head up its Project FDA initiative.

Sens. Klobuchar, Collins push drug-shortage bill

March 01, 2012

U.S. senators Amy Klobuchar and Susan Collins are trying to quickly pass a bill addressing the growing drug shortage problem

User-fee inaction could cause logjam

March 01, 2012

Congressional inaction could lead to a huge new products-review backlog, according to FDA Matters editor Steven Grossman.

As I See It: Political interference in FDA

February 01, 2012

Political interference in FDA's scientific decisions is growing, well-hidden phenomenon

Republican's bill to reform FDA, save jobs

February 01, 2012

Sen. Dan Coats (R-IN) has introduced a bill to clarify and reform FDA's mission in order to keep jobs from going overseas.

New drug sponsors cause FDA chaos

February 01, 2012

"Emerging sponsors" or companies that have never had an approved application to market a drug are wreaking havoc on review activities at FDA's drugs center, says Office of New Drugs director John Jenkins.

New approval paths are needed, says Woodcock

January 01, 2012

FDA director of drugs Janet Woodcock says she is so optimistic that biomedical science and the war on cancer will produce "startlingly better" therapies that the research community should develop new approval paths.

« Previous

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.